Ana-Mihaela Bora, Annalena Muth, Kamyar Shokraee, Siavosh Olfati, Ina Monsef, Juan Víctor Ariel Franco, Nicole Skoetz
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023
10.1016/j.jacc.2025.08.015 · 2025
Unresolved referenced work
Kept as external metadata until matched
Atherosclerotic cardiovascular disease: a review of initiators and protective factors
10.1007/s10787-015-0255-y · 2016
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
10.1016/s2214-109x(19)30318-3 · 2019
2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias
10.1093/eurheartj/ehaf190 · 2025
Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review
10.2174/1573403x16999201210200342 · 2021
Dyslipidemia and the current state of cardiovascular disease: epidemiology, risk factors, and effect of lipid lowering
10.1016/j.cjca.2024.04.017 · 2024
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
10.1016/s0140-6736(04)17018-9 · 2004
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
10.1016/s0140-6736(19)32008-2 · 2020
Barriers to accessibility of medicines for hyperlipidemia in low- and middle-income countries
10.1371/journal.pgph.0002905 · 2024
Point-of-care testing for the analysis of lipid panels: primary care diagnostic technology update
10.3399/bjgp12x630241 · 2012
Point of care testing
10.1136/bmj.322.7297.1285 · 2001
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
The impact of a point-of-care testing device on CVD risk assessment completion in New Zealand primary-care practice: a cluster randomised controlled trial and qualitative investigation
10.1371/journal.pone.0174504 · 2017
Point-of-care testing to promote cardiovascular disease risk assessment: a proof of concept study
10.1016/j.pmedr.2017.05.016 · 2017
Pharmacist-led Interventions to improve medication adherence among patients with multimorbidity: a scoping review
10.2147/ppa.s542881 · 2025
Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists
10.1177/17151635231164989 · 2023
Can we trust published evidence on point-of-care tests for cholesterol? A rapid review
10.1136/bmjopen-2023-080726 · 2025
Advances in treatment of dyslipidemia
10.3390/ijms241713288 · 2023
Unresolved referenced work
Kept as external metadata until matched
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
10.1161/cir.0000000000000625 · 2019
Multidisciplinary teams in clinical lipidology and cardiometabolic care: a National Lipid Association expert clinical review
10.1016/j.jacl.2025.05.002 · 2025
2025 ACC/AHA clinical practice guidelines core principles and development process: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10.1016/j.jacc.2025.06.013 · 2025
Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
10.1002/clc.23935 · 2023
Unmet need for hypercholesterolemia care in 35 low- and middle-income countries: a cross-sectional study of nationally representative surveys
10.1371/journal.pmed.1003841 · 2021
Exploring barriers and facilitators of primary care physicians towards optimising statin therapy in patients with hyperlipidaemia in the very high-risk group: a qualitative study in Singapore
10.1136/bmjopen-2023-073125 · 2023
Measuring public preferences for statin therapy using the smallest worthwhile difference
10.1001/jamainternmed.2025.7958 · 2026
Barriers and facilitators to using statins: a qualitative study with patients and family physicians
10.1016/j.cjco.2020.07.002 · 2020
Low awareness of lipid disorders amongst individuals despite their high prevalence
10.1007/s11845-025-03973-w · 2025
Global guidance for dyslipidaemia management in adults: a scoping review
10.5334/gh.1506 · 2025
A systematic review of the evidence for pharmacist care of patients with dyslipidemia
10.1002/j.1875-9114.2012.01022.x · 2012
Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management
10.1345/aph.1k618 · 2008
Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials
10.1016/j.atherosclerosis.2007.01.023 · 2008
Effects of age, gender and statin dose on lipid levels: results from the VOYAGER meta-analysis database
10.1016/j.atherosclerosis.2017.08.014 · 2017
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia
10.1016/j.jacl.2023.03.008 · 2023
Management of dyslipidemia in HIV-infected patients
10.2217/clp.11.25 · 2011
Lipoprotein metabolism, dyslipidemia, and lipid-lowering therapy in women: a comprehensive review
10.3390/ph17070913 · 2024
Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health
10.1016/j.jclinepi.2013.08.005 · doi-reference
GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions
10.1016/j.jclinepi.2019.10.014 · doi-reference
Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline
10.1136/bmj.l6890 · doi-reference
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score
10.1001/jama.297.6.611 · doi-reference
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
10.1136/bmj.j2099 · doi-reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · doi-reference
Machine learning reduces workload with minimal risk of missing studies: development and evaluation of an RCT classifier for Cochrane reviews
10.1016/j.jclinepi.2020.11.003 · doi-reference
An evaluation of Cochrane Crowd found that crowdsourcing produced accurate results in identifying randomized trials
10.1016/j.jclinepi.2021.01.006 · doi-reference
PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement
10.1016/j.jclinepi.2016.01.021 · doi-reference
Development and validation of study filters for identifying controlled non-randomized studies in PubMed and Ovid MEDLINE
10.1002/jrsm.1425 · doi-reference
Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study
10.1111/hir.12269 · doi-reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · doi-reference
Lipoprotein metabolism, dyslipidemia, and lipid-lowering therapy in women: a comprehensive review
10.3390/ph17070913 · doi-reference
Management of dyslipidemia in HIV-infected patients
10.2217/clp.11.25 · doi-reference
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia
10.1016/j.jacl.2023.03.008 · doi-reference
Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials
10.1016/j.atherosclerosis.2007.01.023 · doi-reference
Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management
10.1345/aph.1k618 · doi-reference
A systematic review of the evidence for pharmacist care of patients with dyslipidemia
10.1002/j.1875-9114.2012.01022.x · doi-reference
Global guidance for dyslipidaemia management in adults: a scoping review
10.5334/gh.1506 · doi-reference
Low awareness of lipid disorders amongst individuals despite their high prevalence
10.1007/s11845-025-03973-w · doi-reference
Barriers and facilitators to using statins: a qualitative study with patients and family physicians
10.1016/j.cjco.2020.07.002 · doi-reference
Measuring public preferences for statin therapy using the smallest worthwhile difference
10.1001/jamainternmed.2025.7958 · doi-reference
Exploring barriers and facilitators of primary care physicians towards optimising statin therapy in patients with hyperlipidaemia in the very high-risk group: a qualitative study in Singapore
10.1136/bmjopen-2023-073125 · doi-reference
Unmet need for hypercholesterolemia care in 35 low- and middle-income countries: a cross-sectional study of nationally representative surveys
10.1371/journal.pmed.1003841 · doi-reference
Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
10.1002/clc.23935 · doi-reference
2025 ACC/AHA clinical practice guidelines core principles and development process: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10.1016/j.jacc.2025.06.013 · doi-reference
Multidisciplinary teams in clinical lipidology and cardiometabolic care: a National Lipid Association expert clinical review
10.1016/j.jacl.2025.05.002 · doi-reference
Effects of age, gender and statin dose on lipid levels: results from the VOYAGER meta-analysis database
10.1016/j.atherosclerosis.2017.08.014 · doi-reference
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
10.1161/cir.0000000000000625 · doi-reference
Advances in treatment of dyslipidemia
10.3390/ijms241713288 · doi-reference
Can we trust published evidence on point-of-care tests for cholesterol? A rapid review
10.1136/bmjopen-2023-080726 · doi-reference
Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists
10.1177/17151635231164989 · doi-reference
Pharmacist-led Interventions to improve medication adherence among patients with multimorbidity: a scoping review
10.2147/ppa.s542881 · doi-reference
Point-of-care testing to promote cardiovascular disease risk assessment: a proof of concept study
10.1016/j.pmedr.2017.05.016 · doi-reference
The impact of a point-of-care testing device on CVD risk assessment completion in New Zealand primary-care practice: a cluster randomised controlled trial and qualitative investigation
10.1371/journal.pone.0174504 · doi-reference
Point of care testing
10.1136/bmj.322.7297.1285 · doi-reference
Point-of-care testing for the analysis of lipid panels: primary care diagnostic technology update
10.3399/bjgp12x630241 · doi-reference
Barriers to accessibility of medicines for hyperlipidemia in low- and middle-income countries
10.1371/journal.pgph.0002905 · doi-reference
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
10.1016/s0140-6736(19)32008-2 · doi-reference
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
10.1016/s0140-6736(04)17018-9 · doi-reference
